Liver Biomarkers in Anorexia Nervosa

Assessment of Liver Damage Using the Fibroscan in Patients With Anorexia Nervosa

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05861375

Acronym

LIBAN

Enrollment

Registered

2023-05-16

Start date

2023-06-23

Completion date

2025-06-27

Last updated

2026-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anorexia Nervosa

Keywords

Liver Fibrosis, Liver Steatosis, Enteral Refeeding, Anorexia Nervosa

Brief summary

The main goal of the Liver Biomarkers in Anorexia Nervosa (LIBAN) study is to determine the prevalence of liver fibrosis in patient with Anorexia Nervosa.

Detailed description

Prevalence of hepatic fibrosis will be non-invasively investigated, in the Anorexia Nervosa inpatient population, using the Fibroscan ®. Furthermore, liver blood markers will be assessed.

Interventions

DIAGNOSTIC_TESTFibroscan

Fibroscan is a non-invasive device that allows liver exploration painlessly, quickly (a few minutes) and with immediate results. A probe placed on the skin generates an elastic wave completely painlessly and the device measures its speed of propagation in the liver. Liver stiffness is calculated from this speed.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

15 Years to No maximum

Healthy volunteers

Inclusion criteria

: * Patient over 15 years old * Diagnosis of Restricted Eating Disorders including Anorexia Nervosa according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) * Admission to the endocrinology, diabetology and nutrition department of the Nantes University Hospital.

Exclusion criteria

: * Chronic active viral hepatitis * Hemochromatosis * Other genetic, autoimmune, toxic or drug-induced hepatitis * Treatment with a drug known to induce fatty liver disease (amiodarone, carbamazepine, tamoxifen, valproate, clozapine, anti-retrovirals) unless the dose has been stable for ≥ 3 months * Excessive alcohol consumption (≥ 30 grams per day in men, ≥ 20 grams per day in women)

Design outcomes

Primary

Measure	Time frame	Description
Liver fibrosis prevalence in patients with Anorexia nervosa	Day one	Liver stiffness will be assessed using Fibroscan (kPA) within the 24 hours following admission to the endocrinology, diabetology and nutrition department.

Countries

France

Contacts

PRINCIPAL_INVESTIGATORSarra SMATI-GRANGEON, PH

Nantes University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 18, 2026